398 related articles for article (PubMed ID: 24058406)
1. Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.
Gardai SJ; Mao W; Schüle B; Babcock M; Schoebel S; Lorenzana C; Alexander J; Kim S; Glick H; Hilton K; Fitzgerald JK; Buttini M; Chiou SS; McConlogue L; Anderson JP; Schenk DB; Bard F; Langston JW; Yednock T; Johnston JA
PLoS One; 2013; 8(8):e71634. PubMed ID: 24058406
[TBL] [Abstract][Full Text] [Related]
2. Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model.
Sommer A; Fadler T; Dorfmeister E; Hoffmann AC; Xiang W; Winner B; Prots I
J Neuroinflammation; 2016 Jun; 13(1):174. PubMed ID: 27364890
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
[TBL] [Abstract][Full Text] [Related]
4. Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease.
Grozdanov V; Bousset L; Hoffmeister M; Bliederhaeuser C; Meier C; Madiona K; Pieri L; Kiechle M; McLean PJ; Kassubek J; Behrends C; Ludolph AC; Weishaupt JH; Melki R; Danzer KM
Ann Neurol; 2019 Oct; 86(4):593-606. PubMed ID: 31343083
[TBL] [Abstract][Full Text] [Related]
5. Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.
Roodveldt C; Labrador-Garrido A; Gonzalez-Rey E; Fernandez-Montesinos R; Caro M; Lachaud CC; Waudby CA; Delgado M; Dobson CM; Pozo D
PLoS One; 2010 Oct; 5(10):e13481. PubMed ID: 21048992
[TBL] [Abstract][Full Text] [Related]
6. Immunological features of alpha-synuclein in Parkinson's disease.
Roodveldt C; Christodoulou J; Dobson CM
J Cell Mol Med; 2008 Oct; 12(5B):1820-9. PubMed ID: 18671754
[TBL] [Abstract][Full Text] [Related]
7. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
8. Expression of mutant alpha-synuclein modulates microglial phenotype in vitro.
Rojanathammanee L; Murphy EJ; Combs CK
J Neuroinflammation; 2011 May; 8():44. PubMed ID: 21554732
[TBL] [Abstract][Full Text] [Related]
9. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease.
Wijeyekoon RS; Kronenberg-Versteeg D; Scott KM; Hayat S; Kuan WL; Evans JR; Breen DP; Cummins G; Jones JL; Clatworthy MR; Floto RA; Barker RA; Williams-Gray CH
Brain Behav Immun; 2020 Jul; 87():473-488. PubMed ID: 32006615
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.
Lastres-Becker I; Ulusoy A; Innamorato NG; Sahin G; Rábano A; Kirik D; Cuadrado A
Hum Mol Genet; 2012 Jul; 21(14):3173-92. PubMed ID: 22513881
[TBL] [Abstract][Full Text] [Related]
11. A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM
Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies to alpha-synuclein in inherited Parkinson's disease.
Papachroni KK; Ninkina N; Papapanagiotou A; Hadjigeorgiou GM; Xiromerisiou G; Papadimitriou A; Kalofoutis A; Buchman VL
J Neurochem; 2007 May; 101(3):749-56. PubMed ID: 17448146
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology.
Dzamko N; Gysbers A; Perera G; Bahar A; Shankar A; Gao J; Fu Y; Halliday GM
Acta Neuropathol; 2017 Feb; 133(2):303-319. PubMed ID: 27888296
[TBL] [Abstract][Full Text] [Related]
14. Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
Butkovich LM; Houser MC; Chalermpalanupap T; Porter-Stransky KA; Iannitelli AF; Boles JS; Lloyd GM; Coomes AS; Eidson LN; De Sousa Rodrigues ME; Oliver DL; Kelly SD; Chang J; Bengoa-Vergniory N; Wade-Martins R; Giasson BI; Joers V; Weinshenker D; Tansey MG
J Neurosci; 2020 Sep; 40(39):7559-7576. PubMed ID: 32868457
[TBL] [Abstract][Full Text] [Related]
15. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
16. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.
Park JY; Paik SR; Jou I; Park SM
Glia; 2008 Aug; 56(11):1215-23. PubMed ID: 18449945
[TBL] [Abstract][Full Text] [Related]
17. Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant.
Hoenen C; Gustin A; Birck C; Kirchmeyer M; Beaume N; Felten P; Grandbarbe L; Heuschling P; Heurtaux T
PLoS One; 2016; 11(9):e0162717. PubMed ID: 27622765
[TBL] [Abstract][Full Text] [Related]
18. CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson's disease.
Li Y; Niu M; Zhao A; Kang W; Chen Z; Luo N; Zhou L; Zhu X; Lu L; Liu J
J Neuroinflammation; 2019 Dec; 16(1):263. PubMed ID: 31831012
[TBL] [Abstract][Full Text] [Related]
19. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease.
Subbarayan MS; Hudson C; Moss LD; Nash KR; Bickford PC
J Neuroinflammation; 2020 Aug; 17(1):242. PubMed ID: 32799878
[TBL] [Abstract][Full Text] [Related]
20. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.
Zhang QS; Heng Y; Yuan YH; Chen NH
Toxicol Lett; 2017 Jan; 265():30-37. PubMed ID: 27865851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
